Sector News

New threat to Shire's hemophilia franchise? CEO Ornskov's not worried

December 14, 2017
Life sciences

Roche’s Genentech is out with a new threat to Shire’s hemophilia franchise in the form of a bispecific antibody dubbed Hemlibra—but the Dublin drugmaker’s CEO, for one, says he is not too concerned.

“I don’t think factor VIII, I don’t think factor IX, I don’t think plasma, I don’t think Feiba is going to go away with any of the things I see here,” Chief Executive Flemming Ornskov said in an interview at the American Society of Hematology (ASH) annual meeting. Those older therapies “will still be part of the treatment options for patients, and in many cases, the foundation of their treatment,” he said.

That’s the outcome Shire needs, at least. Currently a front-runner in hemophilia because of its Baxalta buyout, Shire lags a few years behind some of the leaders in potentially disruptive fields such as gene therapy and bispecific antibodies. That’s because Baxalta “had been a bit starved for resources and innovation” before Shire snapped it up, Ornskov said.

Since then, Shire has done what it can to correct course. It licensed in a bispecific antibody and sped up “all the things that we can do in gene therapy,” Ornskov said. “I think we’ve shown in multiple categories that we can catch up and sometimes overtake some of our competitors,” he said.

For now, though, it’s Roche that has the bispecific antibody lead—and the threat to Shire’s market share—with Hemlibra, a product that snagged approval last month in hemophilia A patients who have developed factor VIII-inhibiting antibodies. Hemlibra put up positive longer-term data at ASH, and consensus estimates peg that product at $2 billion in sales by 2025. Some analysts, such as those at Jefferies, think it could pull in much more if it can move into the larger, noninhibitor population.

But as Ornskov cautioned, while there’s “significant unmet need” in the inhibitor group and “doctors are really welcoming” of another treatment option, they may not be as keen to use Hemlibra in the noninhibitor population, which represented “a more satisfied market.”

“The hurdle both safety-wise and in terms of efficacy is pretty high in that area, so any new agent will have to meet this criteria,” he said, adding that “the unmet need, I’m sure, is also there, but it’s not of the same magnitude.”

What if Hemlibra can snag a green light and manage to poach market share, though? Shire will still be okay, he insisted.

“Hemophilia is 20-plus percent of our business. It is not our largest business,” he said, noting that distinction “by far” belongs to immunology. Still, when it comes to hemophilia, “I feel very confident that with the right investment, the right focus, with the new R&D team that I’m putting in place, that we will do very well and continue to be a leader,” he said.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach